Danne T, Matsuhisa M, Sussebach C, et al. - Researchers conducted this post‐hoc meta‐analysis to analyze the risk of severe hypoglycaemia (SH) with insulin glargine 300 U/mL (Gla‐300) vs glargine 100 U/mL (Gla‐100) in a pooled population with type 1 diabetes (T1DM) from three randomised, multicentre, 6‐month similarly designed phase 3 trials: EDITION 4, EDITION JP 1, and EDITION JUNIOR.  Incidence and time to first occurrence of SH were included endpoints. HbA_1c reductions were identical among 629 and 626 candidates randomized to the Gla‐300 and Gla‐100. With Gla‐300 vs Gla‐100, the SH event rates were numerically lower from baseline to Month 6 and from baseline to Week 8. Thus, particularly during the titration period, Gla‐300 showed similar glycaemic control with lower risk of SH vs Gla‐100.